bluebird bio anticipates the total gross proceeds from the offering
(before deducting underwriters’ discounts and commissions and estimated
offering expenses) will be approximately
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio's gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® product candidate, currently
in five clinical studies for the treatment of transfusion-dependent
β-thalassemia, also known as β-thalassemia major, and severe sickle cell
disease. bluebird bio's oncology pipeline is built upon the company's
leadership in lentiviral gene delivery and T cell engineering, with a
focus on developing novel T cell-based immunotherapies, including
chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies.
bluebird bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA
CAR T programs partnered with
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the anticipated final terms, timing and completion of the proposed
offering, and bluebird bio’s existing product candidates and research
programs. Any forward-looking statements are based on management’s
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the proposed
public offering, that the preliminary results from our clinical trials
will not continue or be repeated in our ongoing clinical trials, the
risk of cessation or delay of any of the ongoing or planned clinical
studies and/or our development of our product candidates, the risk of a
delay in the enrollment of patients in our clinical studies, the risks
that the changes we have made in the LentiGlobin drug product
manufacturing process or the HGB-206 clinical study protocol will not
result in improved patient outcomes, risks that the current or planned
clinical studies of the LentiGlobin drug product will be insufficient to
support regulatory submissions or marketing approval in the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171212006490/en/
Source: bluebird bio, Inc.
Investor Relations and Media
bluebird bio, Inc.
Elizabeth
Pingpank, 617-914-8736
epingpank@bluebirdbio.com